Summary

The mice model market is projected to reach USD 2.2 billion by 2029 from an estimated USD 1.5 billion in 2024, at a CAGR of 8.1% during the forecast period. The growth of this market can be attributed to the research and development efforts aimed at drug discovery and development for novel therapies and employment of mice model in studies, and the growing focus on personalized medicines in oncology.

“The model type segment accounted for the largest share by model type & service in 2023.”
In 2023, the model type segment accounted for the largest share of model type & service segment in the global mice model market. The factors such as the genetic similarity of mice with that of humans, also the mice models play a crucial role in studying human diseases, testing new drugs and therapies, and understanding biological processes are driving the growth of this market.
“The Asia Pacific region is growing at the highest CAGR in the mice model market during the forecast period of 2024-2029.”
The Asia Pacific region is expected to grow at the highest growth rate during the forecast period. Various factors including growing adoption of mice model based pre-clinical studies and booming healthcare sector are propelling the growth of mice model market in the region.
Increased funding and investments from pharmaceutical and biotechnology companies to develop novel technologies are expected to propel the growth of the mice model market in the Asia Pacific region. As the region continues to invest in biomedical research and pharmaceutical development, there is a growing demand for mice models to support preclinical studies and drug discovery efforts. Additionally, the increasing prevalence of chronic diseases in Asia-Pacific countries has fueled the need for reliable animal models to better understand disease mechanisms and test potential therapies.
The primary interviews conducted for this report can be categorized as follows:

• By Respondent: Supply Side- 70% and Demand Side 30%
• By Designation: C-level Executives - 55%, Director-level - 20%, and Others - 25%
• By Region: North America -45%, Europe -20%, Asia-Pacific -20%, Latin America -10%, Middle East-3%, and Africa- 2%
List of Companies Profiled in the Report:
• Charles River Laboratories (US)
• Inotiv (US)
• THE JACKSON LABORATORY (US)
• GemPharmatech (China)
• Cyanogen (US)
• Shanghai Model Organisms Center, Inc. (China)
• JSR Corporation (Japan)
• Biocytogen (China)
• TRANS GENIC INC. (Japan)
• Ozgene Pty Ltd. (Australia)
• Taconic Biosciences, Inc. (US)
• TransCure bioServices (France)
• Harbour BioMed (China)
• Marshall BioResources (US)
• genOway (France)
• Vivo Bio Tech Ltd. (India)
• ingenious targeting laboratory (US)
• Janvier Labs (France)
• Applied StemCell (US)
• Creative Animodel (US)
• JOINN Laboratories Co., Ltd. (China)
• Creative Biolabs (US)
• Crescendo Biologics (UK)
• Aragen Life Sciences (India)
• PolyGene (Switzerland)

Research Coverage:
This research report categorizes the mice model market market by model type & service (model type & service), technology (CRISPR/Cas9, microinjection, embryonic stem cell injection, nuclear transfer, and other technologies), therapeutic area (oncology, neurology, metabolic diseases, immunology, cardiovascular diseases, and other diseases), application (drug discovery & development, research application, and personalized medicine) end user (pharmaceutical & biotechnology companies, academic & research institutes, and CROs and CDMOs), and by region (North America, Europe, Asia Pacific, Latin America, Middle East, and Africa). The report provides in-depth information on significant factors influencing the growth of the mice model market, including drivers, trends, challenges, and opportunities. A thorough analysis of major industry players has been undertaken to provide insights into their business profiles, products/services, key strategies, collaborations, partnerships, and agreements. Additionally, the report encompasses recent developments such as new product launches, mergers, and acquisitions within the mice model market.
Key Benefits of Buying the Report:
The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall mice model market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.
The report provides insights on the following pointers:
• Analysis of key drivers (Genetic & physiological versatility of mice models in preclinical studies, increasing demand for mouse clinical trials (MCTs), rising demand for personalized medicine in oncology, genetic engineering advancement), restraints (Introduction of 3D, ethical concerns and regulatory restrictions), opportunities (Utilization of CRISPR in biomedical research, rising demand for disease-specific models), and challenges (Development of alternative animal testing methods, genetic and phenotypic variability) influencing the growth of the market.
• Product Development/Innovation: Detailed insights on newly launched products/services of the mice model market
• Market Development: Comprehensive information about lucrative markets - the report analyses the market across varied regions.
• Market Diversification: Exhaustive information about new products/services, untapped geographies, recent developments, and investments in the mice model market
• Competitive Assessment: Charles River Laboratories (US), Inotiv (US), THE JACKSON LABORATORY (US), GemPharmatech (China), Cyagen (US), Shanghai Model Organisms Center, Inc. (China), JSR Corporation (Japan), Biocytogen (China), TRANS GENIC INC. (Japan), Ozgene Pty Ltd. (Australia), Taconic Biosciences, Inc. (US), TransCure bioServices (France), Harbour BioMed (China), Marshall BioResources (US), genOway (France), Vivo Bio Tech Ltd. (India), ingenious targeting laboratory (US), Janvier Labs (France), Applied StemCell (US), Creative Animodel (US), JOINN Laboratories Co., Ltd. (China), Creative Biolabs (US), Crescendo Biologics (UK), Aragen Life Sciences (India), and PolyGene (Switzerland), among others in the market.